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Abstract 
Expansions of polyglutamine (polyQ) tracts in different proteins cause 9 
neurodegenerative conditions, such as Huntington disease and various ataxias. 
However, many normal mammalian proteins contain shorter polyQ tracts. As these are 
frequently conserved in multiple species, it is likely that some of these polyQ tracts have 
important but unknown biological functions. Here we review our recent study showing 
that the polyQ domain of the deubiquitinase ATXN3/ataxin-3 enables its interaction 
with BECN1/beclin 1, a key macroautophagy/autophagy initiator. ATXN3 regulates 
autophagy by deubiquitinating BECN1 and protecting it from proteasomal 
degradation. Interestingly, expanded polyQ tracts in other polyglutamine disease 
proteins compete with the shorter ATXN3 polyQ stretch and interfere with the ATXN3-
BECN1 interaction. This competition results in decreased BECN1 levels and impaired 
starvation-induced autophagy, which phenocopies the loss of autophagic function 
mediated by ATXN3. Our findings describe a new autophagy-protective mechanism 
that may be altered in multiple neurodegenerative diseases. 
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 Expansions of polyglutamine (polyQ) tracts in different proteins cause 9 
neurodegenerative conditions, such as Huntington disease and various ataxias. Importantly, 
the wild-type counterparts of these disease proteins have shorter polyglutamine tracts that are 
conserved in many species, suggesting that they have biological functions. The presence of 
the same expansion mutation in different proteins suggests a common pathogenic mechanism. 
One process shared across these diseases is the propensity of the mutant proteins to 
aggregate. While this process has been implicated in pathogenesis, soluble forms of these 
proteins have also been shown to be toxic. However, toxic molecular mechanisms of such 
soluble expanded polyQ-containing species have been elusive.  
When these mutant proteins reside in the cytoplasm, they have a high dependence on 
autophagy for their clearance. This is likely because the aggregated-oligomeric species are 
inaccessible to the proteasome and chaperone-mediated autophagy. Induction of autophagy 
enhances clearance of polyQ-expanded mutant proteins, like mutant HTT (huntingtin) and 
ATXN3, thereby attenuating their toxicity in cell and mouse models of Huntington disease 
and spinocerebellar ataxia, respectively.  
Our recent study revealed that wild-type ATXN3 is a deubiquitinase for BECN1. 
Importantly, we showed that the polyQ domain in wild-type ATXN3 is a key mediator of its 
interaction with the evolutionarily conserved domain of BECN1 (Fig. 1A). This interaction 
enables ATXN3 deubiquitination of BECN1, which protects it from degradation by the 
proteasome. BECN1 is a critical component of the class III phosphatidylinositol 3-kinase 
complex that generates phosphatidylinositol-3-phosphate (PtdIns3P) at autophagy initiation 
membranes and recruits autophagy proteins that are involved in autophagosome nucleation 
(i.e., the WIPI2-ATG16L1 complex). Thus, depletion of ATXN3 causes more rapid BECN1 
degradation, resulting in decreased PtdIns3P formation and decreased autophagosome 
biogenesis.  
The finding that BECN1 contains polyQ binding pockets led us to test whether it 
could bind to proteins with polyQ expansions, and if such proteins would compete with the 
shorter polyQ stretch in ATXN3 for BECN1 binding (Fig. 1B). Our data suggest that isolated 
polyQ tracts are able to bind BECN1, whereas the longer expansions, which cause polyQ 
diseases, bind BECN1 to a greater extent than the shorter forms. Indeed, overexpression of 
disease proteins with polyQs (other than ATXN3) increases BECN1 ubiquitination and its 
degradation. This BECN1 degradation leads to impaired starvation-induced autophagy, a 
phenotype characteristic of BECN1 depletion. For example, we provided evidence, at least by 
overexpression studies, that the HTT exon 1 has these deleterious effects on autophagy. N-
terminal fragments of HTT containing expanded polyQ domains are found in brains of 
Huntington disease patients and cause toxicity in cells and in Huntington disease mouse 
models. Furthermore, full-length mutant HTT binds BECN1 and competes for BECN1 
binding with ATXN3, and fibroblasts from Huntington disease patients have impaired 
starvation-induced autophagy. Importantly, our data suggest that these competition effects 
can be mediated by soluble forms of proteins with polyQ stretches, thereby revealing a 
possible toxic function of nonaggregated mutant proteins with polyQ expansions.  
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The effects described above relate to mutant polyQ proteins competing with ATXN3 
in trans, and these may be relevant to diverse polyglutamine diseases. However, because 
spinocerebellar ataxia type 3, also known as Machado-Joseph disease, is caused by a polyQ 
expansion in the ATXN3 protein itself, we studied its effects. We found that expansion of the 
polyQ tract in ATXN3 decreased its deubiquitinase activity towards BECN1 in an in vitro 
deubiquitination assay. However, the expanded disease-causing polyQ tract makes ATXN3 
interact much more strongly with BECN1 (Fig. 1C). Thus, mutant ATXN3 would 
outcompete the wild-type-protein in this autosomal dominant disease, but the mutant protein 
would have decreased deubiquitinating activity, resulting in decreased BECN1 levels and 
impaired starvation-induced autophagy. Indeed, previous studies have shown that 
autophagosome formation is compromised in fibroblasts from patients with spinocerebellar 
ataxia type 3 and that phenotypes in rodent models of this disease can be ameliorated by 
BECN1 overexpression.  
The phenomena we have described are likely to be one of many mechanisms 
contributing to toxicity by mutant polyQ proteins. Indeed, there may be features of these 
proteins that affect autophagy via distinct mechanisms, as has been reported for mutant HTT. 
Furthermore, our proposed mechanisms will probably be nuanced due to the vast 
heterogeneity of the genetic landscapes associated with these diseases. First, the length of the 
polyQ tract in wild-type ATXN3 is polymorphic in humans, and it would be interesting to 
understand the extent to which this affects binding and activity. Furthermore, the disease 
alleles in all these conditions are also polymorphic in polyQ length, with longer expansions 
causing earlier disease onset. Further work will be required to test if shorter polyQ disease 
alleles have similar effects to longer disease alleles. An additional variable that is likely to 
have an impact on disease is the relative expression levels of ATXN3, the polyQ disease 
protein (e.g., mutant HTT) and BECN1 in different neuronal populations. This may 
contribute to the differential vulnerabilities of different brain regions in these diseases. 
Finally, it would be interesting to test if polyQ-containing cleavage products of some of the 
disease proteins are more toxic in this paradigm, compared to their uncleaved full-length 
counterparts. 
These data raise the question of whether and to what extent polymorphisms in the 
wild-type and expanded polyQ stretches may contribute to the variabilities in clinical onset, 
presentation and progression of these devastating diseases. 
 
 
Figure legend  
Figure 1. A proposed model describing ATXN3 activity in autophagy and its downregulation 
by mutant polyQ disease proteins. (A) The polyQ domain in wild-type ATXN3 (WT-Q) 
interacts with the evolutionarily conserved domain (ECD) of BECN1. This interaction allows 
the deubiquitinase activity of ATXN3 to protect BECN1 from degradation by the proteasome 
and thus enables autophagy. (B) Some expanded polyQ proteins (µ-QQQ) can compete in 
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trans with the shorter polyQ stretch in wild-type ATXN3 for BECN1 binding. This 
competition destabilizes BECN1. (C) Expansion of the polyQ domain in ATXN3 decreases 
the deubiquitinase (DUB) activity towards BECN1 and enhances the interaction of mutant 
ATXN3 with BECN1. This would outcompete wild-type ATXN3 binding to BECN1 and 
destabilizes BECN1. 
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